The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | LAPIS: pamrevlumab for locally advanced pancreatic cancer
Vincent Picozzi, MD, Virginia Mason Medical Center, Seattle, WA, explores the results of the LAPIS trial (NCT03941093), investigating the addition of pamrevlumab to nab-paclitaxel/gemcitabine for locally advanced pancreatic cancer. The trial included two different disease stages and aimed to assess the combination’s potential to improve overall survival and increase the number of patients eligible for surgery by downstaging their tumors. Despite no difference in survival or surgical eligibility, the study’s innovative design may offer insights for future research in pancreatic cancer treatment. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
